1. Scrip
  2. >>Business

Precision Sells Off Autoimmune Rights For Allogeneic CAR-T To TG Therapeutics

 
• By Alaric DeArment

TG, which has seen growing sales for Briumvi in multiple sclerosis, is expanding into CAR-T for immunology as Precision pivots to in vivo gene therapies.

TG and Precision signed a deal for Precision's off-the-shelf CAR-T, both companies having recently made strategic pivots. • Source: Shutterstock

As sales of its CD20-directed monoclonal antibody for multiple sclerosis pick up speed, TG Therapeutics, Inc. is furthering its pivot from oncology into immunology through a deal with Precision BioSciences, Inc. to develop a CD19-directed allogeneic CAR-T cell therapy for autoimmune diseases. Precision itself had announced plans over the summer to exit development of the asset, azercabtagene zapreleucel (azer-cel), and make its own strategic pivot.

TG announced the global licensing deal for exclusive worldwide rights to develop and commercialize azer-cel in non-oncology indications on 9 January, and will pay Precision $17.5m consisting of a $7.5m upfront payment as well as near-term economics

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 
• By Andrew McConaghie

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.

More from Business